



**IPMAR**

IPSC Platform to Model Alzheimer's Disease Risk

# Certificate of analysis

**DRICUi053-A**

Operators: C Bridge/J Winston/R O'Donoghue

Date: 04/06/2026

Supervisor: H Hall-Roberts

Date: 19/06/2026

Signature: *HCRoberts*


# Source of cells and reprogramming information

- ADLON40138CA T cells from Cardiff 16/05/23
- Reprogrammed at UOXF AKA IPMAR60
- Reprogrammed on 05/2023 Sally Cowley/  
Sarah Ellwood (Oxford)
- Reprogramming system Cytotune v2
- Clone DRICUi053-A = IPMAR60A5
- Banked at P12, 21/10/24, Jincy Winston  
(Cardiff)


# Viability post-thaw and Morphology according to JMSCFSOP19 passage 13

- Vial cell count immediately post-thaw  $2.12 \times 10^6$
- Viability immediately post-thaw 95.1%
- Photo at day 2 post-thaw (scale bar =  $100\mu\text{m}$ ):

Day 2 post-thaw, 20% plated to 1w.6wp



# Sendai Cytotune 2 clearance: according to Cytotune manual Virus undetectable at passage 10



Product sizes: SeV 181bp; KOS 528bp; SeV-Klf 410bp; SeV-Myc 532bp; Actin 623bp


# Sterility:

Mycoplasma test performed by Eurofins Genomics on 24/03/2025, undetectable at passage 18.


Visual inspection of thawed cells cultured without antibiotic/antimycotic for 4 days:  
no evidence of bacteria, yeast or fungus.

# Flow cytometric analysis according to JMSCFSOP05 passage 12

**DRICUi053-A TRA-1-60 96.9%**




**DRICUi053-A Nanog 99.8%**



# Illumina GSA SNP analysis according to JMSCFSOP16


- Passage 16
- Identity to parent PBMC confirmed
- Karyotype abnormalities:
  - No gross abnormalities detected vs PBMC

# Alignment of ADLON40138CA PBMC SNPs with DRICUi053-A



Regression Coefficient  $R^2$  : 0.9856

# Karyogram ADLON40138CA PBMC



# Karyogram DRICUi053-A

